ARTES Biotechnology GmbH

ARTES Biotechnology is a well established partner for the pharmaceutical industry providing cell line and process development for bio-pharmaceutical products. We contribute more than 20 years of business experience, a track record of products developed for and marketed by our clients as well as safe, reliable and highly competitive microbial production platforms. A unique virus-like particle technology is specifically available for vaccine developments triggering humoral and cellular immune answer.

ARTES is fully dedicated to support your product development with one or more of the following contributions:

• Cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli and Bacillus) expression platforms
• VLP based antigen presentation
• Lab scale up- and downstream process development
• Supply of nonGMP bulk material (API) for activity and toxicity tests
• Technology transfer to cGMP facilities and scale-up support

ARTES´ VLP technology for antigen presentation is a one-of-a-kind offer specifically designed for vaccine projects. Target epitopes are presented on the surface of chimeric virus-like particles produced in the WHO recommended Hansenula yeast platform. The cell line and purification process are close to a commercially applied HepB vaccine manufacturing. Proof-of-concept has been achieved for avian flu and malaria antigens. The VLP technology is applicable for large and multimeric antigens derived from a large variety of pathogens.

ARTES collaborates in contract R&D on the basis of clearly defined work packages, timelines, milestones and deliverables adapted to our client´s requirement.